|
Market Closed -
Nasdaq
16:00:00 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 1.340 USD | -1.47% |
|
-6.94% | -70.21% |
| 09-22 | RedChip Companies, Inc., FibroBiologics, Inc. - Special Call | |
| 09-15 | FibroBiologics, Inc. announced that it has received $0.500001 million in funding | CI |
Company Valuation: FibroBiologics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 70.17 | 14.96 | 9.322 | - | - |
| Change | - | -78.68% | -37.69% | - | - |
| Enterprise Value (EV) | 70.17 | 14.96 | 9.322 | 9.322 | 9.322 |
| Change | - | -78.68% | -37.69% | 0% | 0% |
| P/E | -5.88x | -0.54x | -0.45x | -0.76x | -0.7x |
| PBR | - | - | - | - | - |
| PEG | 0.1x | -0x | 0x | 0x | -0.08x |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0.5x | -0.41x | -0.33x |
| EV / FCF | -0x | - | -0.53x | -0.39x | -0.29x |
| FCF Yield | -17.2% | - | -190% | -256% | -346% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -6.8 | -8.4 | -3 | -1.763 | -1.913 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -13.74 | -16.65 | -18.53 | -22.95 | -28.37 |
| Net income 1 | -11.16 | -18.65 | -18.51 | -22.96 | -28.04 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 40.000 | 4.498 | 1.340 | 1.340 | 1.340 |
| Nbr of stocks (in thousands) | 1,754 | 3,326 | 6,957 | - | - |
| Announcement Date | 3/31/25 | 2/24/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.45x | - | - | - | 9.46M | |
| 21.82x | 7.74x | 15.55x | 1.36% | 74.33B | |
| 32.35x | 9.35x | 29.12x | 0.04% | 62.26B | |
| 32.02x | 6.83x | 17.73x | -.--% | 27.72B | |
| -73.86x | 14.28x | -68.86x | -.--% | 26.42B | |
| -14.99x | 5.59x | -7.02x | -.--% | 24.62B | |
| 28.25x | 5.33x | 17.69x | -.--% | 20.72B | |
| 1078x | 37.73x | 651.73x | -.--% | 15.1B | |
| 43.37x | 15.89x | 32.23x | 0.35% | 15.01B | |
| 17.67x | 5.26x | 12.29x | -.--% | 14.18B | |
| Average | 116.42x | 12.00x | 77.83x | 0.19% | 28.04B | |
| Weighted average by Cap. | 71.21x | 10.18x | 43.99x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBLG Stock
- Valuation FibroBiologics, Inc.
Select your edition
All financial news and data tailored to specific country editions
